Brain metabolic change as a disease-tracking biomarker for asymptomatic GRN carriers

Takeaway

  • In GRN carriers, preclinical change in brain metabolism can be observed more than 15 years before expected onset of disease.

Why this matters

  • The availability of gene-based and preventive therapies means that monitoring of asymptomatic carriers of GRN variants, a frequent cause of autosomal dominant frontotemporal dementias (FTD) is an unmet need.

  • Detection and continued monitoring of metabolic changes in the brain will facilitate early intervention and therapy response evaluation.